DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d34lgb/cinv_existing_and) has announced the addition of the "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, Apf530 & Rolapitant) - Global Market Opportunity Assessment Study, 2012 - 2018" report to their offering.
This report is an effort to identify factors, which will be the driving force behind the market penetration and corresponding sales of the pipeline chemotherapy-induced nausea and vomiting (CINV) drugs, namely the combination drug netupitant-palonosetron FDC (fixed-dose combination), APF530 and rolapitant, in the next seven years. The report provides extensive analysis of APF530, rolapitant and netupitant-palonosetron (netu-palo) FDC, current market trends, unmet needs and challenges faced by the CINV market and opportunities for these drugs. The report has segregated the pipeline drugs in terms of estimated sales, patient pool and geography.
The study presents a comprehensive assessment of the current clinical trials status and estimated future market penetration of each of these drugs in the CINV market and covers the following content as well:
- Trends and forecast analysis for two prominent geographic markets, namely North America and Europe. Pipeline drug analysis of Asia and RoW (rest of the world) regions are not included in this study as it is assumed that the CINV pipeline drugs would be launched in these regions by 2018 and in the years ahead and so does not come under the scope of the forecast period of this report
- Recent developments of major players and strategies followed by them for gaining competitive advantage
- Profiles of major market participants for better understanding of their contributions
Key Topics Covered:
CHAPTER 1 PREFACE
CHAPTER 2 EXECUTIVE SUMMARY AND MARKET OVERVIEW
CHAPTER 3 CINV MARKET ANALYSIS
CHAPTER 4 CINV PIPELINE DRUGS MARKET ANALYSIS
CHAPTER 5 CINV PIPELINE DRUGS MARKET, BY GEOGRAPHY
CHAPTER 6 COMPETITIVE LANDSCAPE
CHAPTER 7 COMPANY PROFILES
- HELSINN HOLDING S.A.
- MERCK INC.
- TESARO INC.
- AP PHARMA INC.
For more information visit http://www.researchandmarkets.com/research/d34lgb/cinv_existing_and.